Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients

作者：Shu, Qiuhong; Wu, Liyong; Zhang, Ran; Zhang, Qian; Huang, Jingjing; Meng, Yong^*

来源：Scientific Reports, 2019, 9(1): 453.

DOI：10.1038/s41598-018-37520-8

• QUALITY-OF-LIFE
• BETA-BLOCKER THERAPY
• CHINA CURRENT STATUS
• DILATED CARDIOMYOPATHY
• PROGNOSTIC VALUE
• DEPRESSION
• ANXIETY
• IMPACT
• RISK
• INTERVENTION

No previous study reports the effect of age on cardiac performance, motor function and quality of life (QoL) in Chinese chronic heart failure (CHF) patients. This single-center, prospective study enrolled CHF patients with resting heart rate (RHR) > 80 bpm, who were treated with metoprolol and were followed up at 1, 3, 6, and 12 months. Changes in cardiac, motor, and QoL parameters between patients aged >= 60 years and those aged < 60 years were compared at all time points. P < 0.05 was considered significant. A total of 154 patients were enrolled (median age: 66.39 years; 116 aged >= 60 years, 38 aged < 60 years; 95% New York Heart Association class III-IV). RHR decreased significantly in both patient groups (P < 0.0001 for both groups). Patients aged >= 60 years had a significant improvement in both ejection fraction (EF) at 6 and 12 months and in cardiac index (CI) at 3, 6, and 12 months. However, no major difference was observed in motor function in both groups. Significantly higher SF-8 scores showed greater improvement in QoL in the < 60 age group at 12 months (P = 0.0008). Metoprolol demonstrated improvement in cardiac performance, motor function, QoL, and anxiety with increase in depression and burnout in both genders; however, the findings were independent of age.

• 出版日期2019-1-24
• 单位昆明医科大学